JP2020531593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531593A5 JP2020531593A5 JP2020533357A JP2020533357A JP2020531593A5 JP 2020531593 A5 JP2020531593 A5 JP 2020531593A5 JP 2020533357 A JP2020533357 A JP 2020533357A JP 2020533357 A JP2020533357 A JP 2020533357A JP 2020531593 A5 JP2020531593 A5 JP 2020531593A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- phenyl
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1713962.7A GB201713962D0 (en) | 2017-08-31 | 2017-08-31 | Compounds |
| GB1713962.7 | 2017-08-31 | ||
| PCT/EP2018/073431 WO2019043139A1 (en) | 2017-08-31 | 2018-08-31 | FUSED [1,2,4] THIADIAZINE DERIVATIVES AS KAT INHIBITORS OF THE MYST FAMILY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531593A JP2020531593A (ja) | 2020-11-05 |
| JP2020531593A5 true JP2020531593A5 (enExample) | 2021-10-14 |
| JP6975860B2 JP6975860B2 (ja) | 2021-12-01 |
Family
ID=60050736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533357A Expired - Fee Related JP6975860B2 (ja) | 2017-08-31 | 2018-08-31 | Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210380548A1 (enExample) |
| EP (1) | EP3676266A1 (enExample) |
| JP (1) | JP6975860B2 (enExample) |
| CA (1) | CA3073794A1 (enExample) |
| GB (1) | GB201713962D0 (enExample) |
| WO (1) | WO2019043139A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112028850B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠的中间体化合物 |
| CN112028851B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠中间体化合物 |
| WO2021030278A1 (en) * | 2019-08-12 | 2021-02-18 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| CA3189410A1 (en) | 2020-07-15 | 2022-01-20 | Pfizer Inc. | Kat6 inhibitor methods and combinations for cancer treatment |
| CN117597341A (zh) | 2021-08-10 | 2024-02-23 | 江苏恒瑞医药股份有限公司 | 磺酰胺衍生物、其制备方法及其在医药上的应用 |
| EP4561571A1 (en) | 2022-07-29 | 2025-06-04 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| EP4663635A1 (en) | 2023-02-10 | 2025-12-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfonamide derivative and preparation method therefor |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002514192A (ja) * | 1996-11-13 | 2002-05-14 | セフアロン・インコーポレーテツド | ベンゾチアゾおよび関連の複素環基を含有するシステインおよびセリンプロテアーゼ阻害剤 |
| DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| GB201510019D0 (en) * | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-08-31 GB GBGB1713962.7A patent/GB201713962D0/en not_active Ceased
-
2018
- 2018-08-31 US US16/642,290 patent/US20210380548A1/en not_active Abandoned
- 2018-08-31 EP EP18762297.2A patent/EP3676266A1/en not_active Withdrawn
- 2018-08-31 JP JP2020533357A patent/JP6975860B2/ja not_active Expired - Fee Related
- 2018-08-31 WO PCT/EP2018/073431 patent/WO2019043139A1/en not_active Ceased
- 2018-08-31 CA CA3073794A patent/CA3073794A1/en not_active Abandoned